Literature DB >> 8670326

Sicca syndrome associated with hepatitis C virus infection.

C Jorgensen1, M C Legouffe, P Perney, J Coste, B Tissot, C Segarra, C Bologna, L Bourrat, B Combe, F Blanc, J Sany.   

Abstract

OBJECTIVE: To determine the prevalence of hepatitis C virus (HCV) infection in patients with sicca syndrome, and to determine the clinical, immunologic, and genetic characteristics of sicca syndrome associated with HCV.
METHODS: We conducted a prospective study in a university hospital immunology-rheumatology department. Sixty-two consecutive patients with sicca syndrome according to the European criteria for Sjögren's syndrome were included. HCV infection was diagnosed in patients with positive recombinant immunoblot assay findings and the presence of viral RNA in serum and saliva. Rheumatoid factor (RF), cryoglobulins, antinuclear antibodies, and anti-SS-A/SS-B antibodies were sought. HLA typing was performed on all patients.
RESULTS: The prevalence of HCV infection in patients with sicca syndrome was 19%. The incidence of neurologic involvement was significantly increased in patients with sicca syndrome associated with HCV infection (24% versus 4%; P < 0.03), as was elevations in transaminase levels (87.5% versus 16%; P < 0.0001). RF and cryoglobulins were more frequent in HCV-positive sicca syndrome patients (62% versus 30%; P < 0.03, and 56% versus 10%; P < 0.001, respectively). In contrast, anti-SS-A/SS-B antibodies were present in 38% of HCV-negative sicca syndrome patients, but in only 1 HCV-positive sicca syndrome patient (P < 0.01). No significant difference in HLA type was observed. Viral RNA was present in the saliva of 83% of HCV-positive sicca syndrome patients, but in none of the HCV-negative sicca syndrome patients.
CONCLUSION: We observed a high prevalence of HCV infection in our patients with sicca syndrome. HCV-positive sicca syndrome patients had specific clinical characteristics and were seronegative for SS-A/SS-B antibodies. Moreover, HCV RNA was present in the saliva of patients with HCV-associated sicca syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670326     DOI: 10.1002/art.1780390714

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  Is hepatitis C virus a sialotropic virus?

Authors:  M Ramos-Casals; M Garcia-Carrasco; R Cervera; J Font
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 2.  Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.

Authors:  Ibtisam Al-Hashimi
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders.

Authors:  Deng-Ho Yang; Ling-Jun Ho; Jenn-Haung Lai
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Cryoglobulins are not essential.

Authors:  M Trendelenburg; J A Schifferli
Journal:  Ann Rheum Dis       Date:  1998-01       Impact factor: 19.103

5.  High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners.

Authors:  P Fabris; D Infantolino; M R Biasin; G Marchelle; E Venza; V Terribile Wiel Marin; P Benedetti; G Tositti; V Manfrin; F de Lalla
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

6.  Anti-ENA antibodies in patients with chronic hepatitis C virus infection.

Authors:  E D'Amico; C Palazzi; P Cacciatore; A Canelli; G Ursitti; L Cosentino; V Dogali; G Riario-Sforza; F Capani
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

7.  Anti-ENA antibody profiles in patients with hepatitis C virus infection.

Authors:  Christine M Litwin; Angela R Rourk
Journal:  J Clin Lab Anal       Date:  2017-06-12       Impact factor: 2.352

Review 8.  Autoimmunity and infection in Sjögren's syndrome.

Authors:  Ann Igoe; R Hal Scofield
Journal:  Curr Opin Rheumatol       Date:  2013-07       Impact factor: 5.006

9.  Sjögren's syndrome: History, clinical and pathological features.

Authors:  A L Parke; W W Buchanan
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

Review 10.  Oral manifestations of hepatitis C virus infection.

Authors:  Marco Carrozzo; Kara Scally
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.